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Inflammatory mediators may reflect a role of systemic inflammation in the neurodegenerative process of Parkinson’s disease (PD).
Interleukin-6 (IL-6) and chemokine ligand 5 (CCL5), also known as RANTES (regulated on activation, normal T cell expressed and
secreted), have been implicated in neurodegenerative diseases including PD. Serum levels of RANTES and IL-6 of 78 consecutive
PD patients and age-matched 80 controls were measured. Patients with PD had higher RANTES and IL-6 levels compared with the
controls.We found that serumRANTES levels strongly correlated with Hoehn-Yahr score and disease duration in PD patients.This
study indicated that patients with PD have an on-going systemic inflammatory profile where the elevated peripheral production of
RANTES may play a role in the neurodegenerative process.
1. Introduction
Parkinson’s disease (PD), a common neurodegenerative dis-
ease among the elderly, is characterized by resting tremor,
slowness of movement, rigidity, and postural instability.
Although the etiology of PD still remains under investigation,
accumulating data have revealed that the neuroinflammatory
mechanisms contribute to the neurodegenerative process of
PD [1, 2]. In a PD-affected brain, a sustained activation of
microglial cells in the substantia nigra indicates an over-
activation of neuroinflammation in PD progression [2–4].
Interleukin-6 (IL-6) is one of the primary proinflammatory
chemokines involved in the augmentation of inflammation.
A study reported that circulating level of IL-6 was elevated
in the PD patients on average 4.3 years before the diagnosis,
suggesting that the inflammation state was not limited in
the local central region but expanded to the peripheral ones
[5]. Another proinflammatory chemokine RANTES (known
as regulated on activation, normal T cell expressed and
secreted) has been implicated in the recruitment of immune
cells, fundamental regulation of immunoreactions, and hence
the maintenance of inflammatory states [6]. Evidences have
shown that RANTES and its receptor CCR5 play a role in a
wide array of pathological conditionswith neurodegenerative
diseases such as PD, Alzheimer’s disease (AD), multiple
sclerosis, stroke, and HIV-associated dementia [7–9]. How-
ever, the systemic profiles of RANTES and IL-6 in PDpatients
have not been fully established. Hence, we investigated the
relationship between RANTES, IL-6 levels, and the severity
of the disease in PD patients, intending to describe the
peripheral inflammatory profiles of PD patients.
2. Experimental Procedure
2.1. Patients and Controls. PD patients (𝑛 = 78) who fulfilled
the UK Parkinson’s Disease Society Brain Bank Clinical
Diagnostic Criteria were registered from the clinic of Shaanxi
Provincial People’s Hospital from October 2008 to May 2011
in a consecutive way. All included subjects with a clinical
history of active infectious or systemic inflammatory disease
or patients taking corticosteroids were excluded. PD patients
were evaluated with UPDRS and Hoehn-Yahr score during
their “off” period. The information about antiparkinsonian
medications was also analyzed. The approval from the Ethics
Committee of Shaanxi Provincial People’s Hospital was
obtained and written informed consent was provided by all
of the participants before enrollment into the study.
Age and sex matched volunteers (𝑛 = 80) were recruited
from Physical Examination Center of Shaanxi Provincial
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Alcohol habits 12 16
Age (years) 76.3 ± 5.0 75.4 ± 4.4
H-Y scale 2.60 ± 1.26
Duration (years) 5.51 ± 5.21
UPDRS I 2.85 ± 2.12
UPDRS II 13.88 ± 7.108
UPDRS III 27.15 ± 12.42
RANTES (ng/mL) 36.72 ± 16.61∗ 31.13 ± 10.65
IL-6 (pg/mL) 4.67 ± 3.64# 2.66 ± 1.91
Data are presented as mean ± SD. PD: Parkinson’s disease; CTRL: control
group; H-Y scale: Hoehn-Yahr scale; UPDRS: Unified Parkinson’s Disease
Rating Scale; RANTES: regulated on activation, normal T cell expressed and
secreted; IL-6: interleukin-6.
∗
𝑃 = 0.013 and #𝑃 < 0.001 versus CTRL (Student’s 𝑡-test).
People’s Hospital, which was defined as the control group of
study. All people from this group were healthy and showed
no parkinsonian symptoms.
2.2. RANTES and IL-6 Measurement. Blood samples (5mL)
from patients and controls were collected in the morning
(8:00–10:00) after an overnight fast with a serum separator
tube and clot for 30 minutes at room temperature before
centrifugation for 15 minutes at 1000×g. Then the serum was
collected and the samples were stored at −80∘C for later anal-
ysis. The Quantikine human CCL5/RANTES and IL-6 from
R&D systems (Minneapolis, MN, USA) were, respectively,
used formeasuring RANTES and IL-6 in serumof all patients
and controls. The optical density was determined at 450 nm
and 570 nm.
2.3. Statistical Analysis. Results are expressed as the mean
± SE unless otherwise specified. Student’s 𝑡-test was used
to assess group difference. Spearman’s correlation coefficient
was applied to test all correlations. Results with probability
less than 5% (𝑃 < 0.05) were considered statistically signif-
icant. Statistical analyses were performed using SPSS for
Windows, version 13.0 (SPSS Inc., Chicago, Illinois, USA).
3. Results
Clinical and demographical characteristics of patients and
controls are summarized in Table 1 and Figures 1-2. There
was no significant difference between patients and controls
with respect to the age, sex, smoking, and alcohol habits.
The PD group showed significantly increased RANTES and
IL-6 levels compared to the controls (𝑃 = 0.013 and 𝑃 <
0.001, resp.). The serum RANTES and IL-6 levels showed
no significant difference between subgroups of PD patients
treated and not treated with antiparkinson drugs (Table 2).
















Figure 1: Significant positive correlation between RANTES and H-
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Figure 2: Significant positive correlation between RANTES and
disease duration in PD patients (𝑛 = 78, 𝑟 = 0.275, 𝑃 = 0.015).
Hoehn-Yahr score, which scaled the severity of PD (𝑛 = 78,
𝑟 = 0.362, 𝑃 = 0.001). There was a significant positive corre-
lation between RANTES and disease duration in PD patients
(𝑛 = 78, 𝑟 = 0.275, 𝑃 = 0.015). However, there were no asso-
ciations between RANTES serum levels and UPDRS I,
UPDRS II, and UPDRS III (data not shown). Unexpectedly,
IL-6 levels were not correlated with Hoehn-Yahr scores,
disease duration, and UPDRS I, UPDRS II, and UPDRS III
(data not shown).
4. Discussion
Several lines of studies have demonstrated that some periph-
eral inflammatory surrogates such as TNF-alpha [10, 11], IL-
6 [12, 13], and IL-10 [14] as well as RANTES are elevated
in PD patients. Our study has confirmed that RANTES and
IL-6 serum levels increased in PD patients compared with
sex- and age-matched subjects. To extend the finding, we
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Table 2: Characteristics of untreated and treated subgroups of PD patients.
Subjects Untreated L-Dopa Agonist∗ 𝑃
𝑁 21 36 21
M/F 17/4 27/9 16/5 NS
Age (years) 75.7 ± 5.4 77.2 ± 4.9 75.3 ± 4.6 NS
Duration (years) 3.22 ± 5.13 7.03 ± 4.48 5.21 ± 5.76 0.025
RANTES (ng/mL) 38.28 ± 19.28 33.0 ± 14.51 41.54 ± 16.41 NS
IL-6 (pg/mL) 5.20 ± 3.20 4.16 ± 3.99 5.01 ± 3.46 NS
Data are presented as mean ± SD. PD: Parkinson’s disease; RANTES: regulated on activation, normal T cell expressed and secreted; IL-6: interleukin-6; NS:
not significant.
∗Combination of agonist with L-dopa 𝑛 = 18, agonist monotherapy 𝑛 = 3.
further investigated the association between RANTES and
PD severity. We found that there was a strong correlation
between RANTES levels and Hoehn-Yahr scores as well as
disease duration in PD patients, showing that serum con-
centration of RANTES increased in a stepwise fashion with
Hoehn-Yahr scores, reflecting that the peripheral RANTES
level may indicate the severity of PD symptoms. In this
regard, RANTES may be served as a surrogate biomarker
in the evaluation of the PD severity. Since the deterioration
rate is heterogeneous among PD patients, the finding of a
biomarker relevant to the severity of PD may be beneficial
to the diagnosis and monitoring of the disease in a clinical
context.
Meanwhile, our data support the notion that a chronically
systemic inflammation state may play a role in the progres-
sion of PD.Multiple studies have indicated that there is a cross
talk between systematic inflammation and neuronal damage
in neurodegenerative diseases. For instance, in primary
neurodegenerative diseases such as PD and AD, the initial
event may be a nonimmune-mediated injury within the
central nervous system.However, accompaniedwith the local
resident microglial activation, peripheral immune cells such
as macrophages and monocytes as well as lymphocytes were
recruited into the injured site, under certain conditions, and
elicited a secondary inflammatory reaction, which is believed
to contribute to the neuronal damage, where a list of key
proinflammatory mediators, including IL-6 and RANTES,
plays a profound role [1, 2]. Thus, the inflammation profile
in PD appeared to be not merely a local substantia nigra
involvement, but a systematic inflammation disorder.
The correlation between the elevated serumRANTES and
the severity of the disease may be attributed to the following
possibilities. One possibility could be due to the leakage of
RANTES from the inflammatory reaction region in the CNS,
since the sustained neuroinflammation-induced vicious cycle
may facilitate the neuronal damage as in PD progression,
in which a host of proinflammatory factors such as IL-6,
TNF-𝛼, and chemokines was overexpressed in the specific
site in the brain and these factors could leak through blood-
brain barriers, thus causing an elevated RANTES level in the
peripheral blood. It does not seem to be reasonable, however,
because the concentration of RANTES in the cerebral spinal
fluid (CSF) of the patients with ALS is far lower (under
1 ng/mL) than that in the peripheral blood (over 90 ng/mL)
[15]. Another explanation for the elevated serum RANTES
level could be the increased production of RANTES in the
blood itself. It was reported that the RANTES concentration
in culture supernatants of the total peripheral bloodmononu-
clear cells from PD patients was 1.7 times higher than that in
healthy controls when challengedwith LPS byReale et al. [16].
Meanwhile, platelets can bind and internalize IgG-coated
particles and then become activated and capable of releasing
RANTES [17]. Moreover, platelet antigen-1a antibody was
capable of inducing the release of RANTES from human
platelets in vitro [18]. Thus the correlation between RANTES
serum levels and disease severity reflects an important role of
peripheral inflammatory states in PD progression.
The reasons for the lack of association between IL-6 levels
and the severity of the disease are unclear. First, we could not
exclude the possibility of chance or unmeasured confounding
as alternative explanations for this. Furthermore, single point
measurements of plasma biomarkers of inflammation are
subject to day-to-day variations. In addition, the small sample
size limited our statistical power in the analyses. Finally,
differences in clearance of IL-6 and RANTES could partially
explain the difference.
A previous study found a significant correlation between
RANTES levels and UPDRS III score [19]; however, in our
investigation we failed to address a correlation between
RANTES levels and UPDRS III scores. The discrepancy
between the two results may result from the difference of
average age of PD patients enrolled in the studies.The average
age of the patients was younger in the previous study than
that in our study (67.5 versus 76.3 years). Meanwhile, it was
considered that rigidity and bradykinesia scores were higher
among old-aged PDpatients than that inmiddle-aged ones in
UPDRS assessment [20]. Further, it was believed that UPDRS
III assessment exhibitedmore sensitivity in tremor-dominant
patients than in rigidity- and bradykinesia-dominant subjects
[21]. Therefore, the confounding factor of average age may
impact the correlation between RANTES levels and UPDRS
III score. In this regard, our study suggested a more reliable
and sensitive assessment instrument dedicated to the rigidity-
and bradykinesia-dominant PD patients was needed.
The present study had some limitations. Although serum
RANTES levels were correlated with Hoehn-Yahr score and
disease duration in PD patients, the relatively low value of
𝑟 presented a weak positive linear relationship. Thus, more
powerful inflammatory biomarkers reflecting the severity of
PD should be investigated. In addition, PD is a heterogeneous
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disease where genetic and environmental causes are involved.
It would be plausible to consider that inflammation process
may be influenced by both environmental conditions and
genetic backgrounds. Thus, environmental exposition and
genetic analysis should be incorporated in the following
study.
5. Conclusion
This study demonstrates that increased serumRANTES levels
in PD patients were associated with the severity of PD,
which points to importance of the systemic inflammation
in PD progression. Future studies should be conducted to
elucidate the exact origination of the elevated RANTES and
the contribution of peripheral RANTES in PD progression.
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[18] M. Dettke, M. Dreer, P. Höcker, and S. Panzer, “Human platelet
antigen-1a antibodies induce the release of the chemokine
RANTES from human platelets,” Vox Sanguinis, vol. 81, no. 3,
pp. 199–203, 2001.
[19] M. Rentzos, C. Nikolaou, E. Andreadou et al., “Circulating
interleukin-15 and RANTES chemokine in Parkinson’s disease,”
Acta Neurologica Scandinavica, vol. 116, no. 6, pp. 374–379, 2007.
[20] N. J. Diederich, C. G. Moore, S. E. Leurgans, T. A. Chmura,
and C. G. Goetz, “Parkinson disease with old-age onset: a com-
parative study with subjects with middle-age onset,” Archives of
Neurology, vol. 60, no. 4, pp. 529–533, 2003.
[21] M. Richards, K. Marder, L. Cote, and R. Mayeux, “Interrater
reliability of the unified parkinson’s disease rating scale motor
examination,”Movement Disorders, vol. 9, no. 1, pp. 89–91, 1994.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
